QbD-Driven Development and Evaluation of Nanostructured Lipid Carriers (NLCs) of Olmesartan Medoxomil employing Multivariate Statistical Techniques.
CONCLUSIONS: Overall, the presented studies indicated successful development of NLCs using multivariate statistical approaches for improved product and process understanding.
PMID: 29048242 [PubMed - as supplied by publisher] (Source: Drug Development and Industrial Pharmacy)
Source: Drug Development and Industrial Pharmacy - October 21, 2017 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Comments on: “Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension”
(Source: European Journal of Drug Metabolism and Pharmacokinetics)
Source: European Journal of Drug Metabolism and Pharmacokinetics - September 11, 2017 Category: Drugs & Pharmacology Source Type: research
Comparison of long ‐term safety of fixed‐dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide
This 52‐week, randomized, open‐label study evaluated long‐term safety/tolerability of fixed‐dose combination azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) vs fixed‐dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with essential hypertension (stage 2; clinic systolic blood pressure 160–190 mm Hg). Initial AZL‐M/CLD 40/12.5 mg/d (n=418) or OLM/HCTZ 20/12.5 mg/d (n=419) could be uptitrated during weeks 4 to 52 (AZL‐M/CLD to 80/25 mg; OLM/HCTZ to 40/25 mg [United States] or 20/25 mg [Europe]) to meet blood pressure targets. Treatment‐emergent adverse events/serious ad...
Source: The Journal of Clinical Hypertension - July 6, 2017 Category: Cardiology Authors: Joel M. Neutel, William C. Cushman, Eric Lloyd, Bruce Barger, Alison Handley Tags: ORIGINAL PAPER Source Type: research
Bioequivalence Study of a New Fixed-Dose Combination Tablet Containing S-Amlodipine Nicotinate and Olmesartan Medoxomil in Healthy Korean Male Subjects.
Abstract
PURPOSE: A fixed-dose combination (FDC) pill of amlodipine (relatively old calcium channel blocker as dihydropyridine) and olmesartan (relatively new angiotensin II receptor blocker) is used for hypertension that is not adequately controlled with a single-formulation drug. Because the FDC is a one-pill formulation, and amlodipine and olmesartan have different mechanisms of action, it is expected to improve patients' medication compliance and have an increased blood pressure-lowering efficacy. The purpose of this study was to assess the safety profile and the bioequivalence of two different FDC for...
Source: Clinical Therapeutics - June 15, 2017 Category: Drugs & Pharmacology Authors: Oh MJ, Hwang HH, Kim HG, Lee GH, Cho YS, Lee SY, Kang SY, Cho KH, Lee YY, Lee YJ, Jang CG, Lee SY Tags: Clin Ther Source Type: research
Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control
AbstractRecent epidemiological surveys have demonstrated that effective and sustained blood pressure (BP) control is achieved in a relatively small proportion of treated hypertensive patients. Indeed, treatment of hypertension represents a key strategy for preventing coronary artery disease, stroke, congestive heart failure and cardiovascular death. Several interventions have been proposed by international guidelines for ameliorating hypertension management and control, mostly including integrated and multi-dimensional pharmacological and non-pharmacological strategies. In particular, numerous evidence demonstrated that a ...
Source: High Blood Pressure and Cardiovascular Prevention - June 12, 2017 Category: Cardiology Source Type: research
Autoimmune ‐like chronic hepatitis induced by olmesartan
This article is protected by copyright. All rights reserved. (Source: Hepatology)
Source: Hepatology - April 24, 2017 Category: Internal Medicine Authors: Sandrine Barge, Marianne Ziol, Jean ‐Charles Nault Tags: Clinical Observations in Hepatology Source Type: research
Olmesartan medoxomil
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2017 Category: Drugs & Pharmacology Source Type: research
Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation.
Authors: B A, D N, Veerabrahma K
Abstract
The aim was to enhance the oral bioavailability of olmesartan medoxomil (OM) by preparing solid lipid nanoparticles (SLNs) and comparing with nanosuspension (OM-NS). OM-SLNs and OM-NS were prepared by known methods. Prepared SLNs were evaluated for physical characters and in vivo pharmacokinetic (PK) performance in rats. OM-NS showed more than four-fold increase in the solubility. During DSC and XRD studies, drug incorporated in SLNs was found to be in amorphous form. The relative bioavailability of OM-SLN and OM-NS was 7.21- and 3.52-fold when compared with that o...
Source: Artificial Cells, Nanomedicine and Biotechnology - March 17, 2017 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation
. (Source: Artificial Cells, Blood Substitutes, and Biotechnology)
Source: Artificial Cells, Blood Substitutes, and Biotechnology - March 14, 2017 Category: Biotechnology Authors: Arun B. Narendar D. Kishan Veerabrahma Source Type: research
Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study)
Background: Olmesartan and azilsartan, angiotensin II receptor blockers (ARBs), are expected to decrease blood pressure more than the other ARBs. We conducted randomized-controlled trials to compare the practical efficacy of olmesartan with azilsartan.
Methods: Eighty-four patients treated with the conventional ARBs for more than 3 months were assigned randomly to receive either 20 mg of olmesartan (olmesartan medoxomil, OL group) or 20 mg of azilsartan (azilsartan, not azilsartan medoxomil, AZ group) once daily for 16 weeks. The practical efficacy on blood pressure was compared between the OL and AZ groups.
Results:...
Source: Blood Pressure Monitoring - March 11, 2017 Category: Cardiology Tags: Clinical Trial Source Type: research
Development of olmesartan medoxomil optimized nanosuspension using Box-Behnken design to improve oral bioavailability.
Authors: K N, D N, V K
Abstract
The aim of present investigation was to enhance the oral bioavailability of olmesartan medoxomil by improving its solubility and dissolution rate by preparing nanosuspension (OM-NS), using Box-Behnken design. In this, four factors were evaluated at three levels. Independent variables include: concentration of drug (X1), concentration of surfactant (X2), concentration of polymer (X3) and number of homogenization cycles (X4). Based on preliminary studies the size (Y1), zeta potential (Y2) and % drug release at 5min (Y3) were chosen as dependent responses. OM-NS were prepared b...
Source: Drug Development and Industrial Pharmacy - March 10, 2017 Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability
Publication date: 1 June 2017 Source:Colloids and Surfaces B: Biointerfaces, Volume 154 Author(s): Vikram Kaithwas, Chander Parkash Dora, Varun Kushwah, Sanyog Jain The current study explores the potential of nanostructured lipid carriers (NLCs) for oral bioavailability enhancement of olmesartan medoxomil (OLM) by systemic design approach. OLM-NLC was successfully prepared with optimized process parameters (i.e. amount of liquid lipid, total amount of lipid, drug content and surfactant concentration) using the Box-Behnken design of experiments for different response parameters (i.e. particle size, Polydispersity inde...
Source: Colloids and Surfaces B: Biointerfaces - March 8, 2017 Category: Biochemistry Source Type: research
Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
Abstract
The current study explores the potential of nanostructured lipid carriers (NLCs) for oral bioavailability enhancement of olmesartan medoxomil (OLM) by systemic design approach. OLM-NLC was successfully prepared with optimized process parameters (i.e. amount of liquid lipid, total amount of lipid, drug content and surfactant concentration) using the Box-Behnken design of experiments for different response parameters (i.e. particle size, Polydispersity index and entrapment efficiency). Further, optimized formulation was validated which depicted nano size, homogenous distribution with optimum entrapm...
Source: Colloids and Surfaces - March 5, 2017 Category: Biotechnology Authors: Kaithwas V, Dora CP, Kushwah V, Jain S Tags: Colloids Surf B Biointerfaces Source Type: research
Management of Hypertension Using Olmesartan Alone or in Combination
In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients. (Source: Cardiology and Therapy)
Source: Cardiology and Therapy - March 2, 2017 Category: Cardiology Source Type: research
